CORPORATE RELEASE
15 MAY 2024

Financial report for the period 1 January to 31 March 2024

Lundbeck grows strategic brands by +17% CER reaching total revenue of DKK 5.3 billion in the first quarter of 2024

Key highlights

Lundbeck's revenue increased by 7% CER[1] (+5% DKK) to DKK 5,288 million in the first quarter of 2024, mainly driven by growth in the U.S. and Europe

- United States: DKK 2,498 million (+9% CER; +7% DKK)
- Europe: DKK 1,248 million (+9% CER; +6% DKK)
- International Markets: DKK 1,481 million (+4% CER; -1% DKK)

The revenue of Lundbeck's strategic brands increased by 17% CER (+15% DKK), reaching DKK 3,759 million, representing 71% of total revenue

- Brintellix®/Trintellix®: DKK 1,168 million (+11% CER; +8% DKK)
- Rexulti®: DKK 1,115 million (+7% CER; +5% DKK)
- Abilify Maintena®/Asimtufii: DKK 859 million (+10% CER; +9% DKK)
- Vyepti®: DKK 617 million (+79% CER; +76% DKK)

Adjusted EBITDA[2] decreased to DKK 1,746 million (-2% CER; -5% DKK) as a result of a lower adjusted gross margin, following quarterly fluctuations in stock valuation. In addition, the first quarter of 2024 reflects higher R&D costs to support the pipeline in progress and targeted investments in sales and promotion mainly for Rexulti® and Vyepti® in the U.S.

Adjusted EBITDA margin reached 33.0% equivalent to a decrease of 3.6 percentage points. Adjusted earnings per share (EPS) reached DKK 1.38 (+1%). Excluding the effect from quarterly fluctuations in stock valuation, the underlying growth in the adjusted EBITDA was 6% CER, constituting an adjusted EBITDA margin decrease of 0.6 percentage points.

In connection with the corporate release, Lundbeck's President and CEO, Charl van Zyl said:
"I am pleased to present another solid quarter for Lundbeck with a robust operational performance and a 7% revenue growth driven by the continued strong performance of our strategic brands. In line with our Focused Innovator strategy, we are driving forward promising scientific innovations such as our potential first-in-class therapy for migraine prevention, anti-PACAP, and a possible first treatment option targeting the rare neurological condition, Multiple System Atrophy."

Key figures

DKK million	Q1 2024	Q1 2023	*Change (CER)[1]*	*Change (DKK)*
Revenue	**5,288**	5,044	*7%*	*5%*
EBITDA	**1,746**	1,744	*4%*	*0%*
Adjusted EBITDA	**1,746**	1,845	*(2%)*	*(5%)*
EPS (DKK)	**1.01**	0.89		*13%*
Adjusted EPS (DKK)	**1.38**	1.36		*1%*

[1] Change at CER (Constant Exchange Rates) does not include effects from hedging.
[2] EBITDA refers to Earnings Before Interest, Taxes, Depreciation and Amortization. Adjusted EBITDA is defined as EBITDA adjusted by certain items, for details see section 4 *Notes*, note 3 *Adjusted EBITDA.*

Recent events

On 30 April 2024, U.S. Food and Drug Administration (FDA) communicated to Lundbeck that Lu AF82422 orphan drug designation request has been granted for treatment of Multiple System Atrophy (MSA).

On 9 April 2024, Lundbeck and Otsuka Pharmaceutical Co., Ltd. submitted a supplemental New Drug Application (sNDA) for U.S. FDA review of brexpiprazole as combination therapy with sertraline for the treatment of post-traumatic stress disorder (PTSD) in adults. The sNDA submission is based on previously disclosed results, including data from the two clinical phase III trials and the clinical phase II trial. All three trials investigated the treatment of PTSD in adults treated with brexpiprazole in combination with sertraline versus sertraline plus placebo.

On 27 March 2024, Lundbeck and Otsuka Pharmaceutical Europe Ltd. announced that the European Commission (EC) has approved Abilify Maintena® 960 mg (aripiprazole) as a once-every-two-months long-acting injectable (LAI) formulation for the maintenance treatment of schizophrenia in adult patients stabilized with aripiprazole. The EC decision applies to all European Union (EU) member states, as well as Iceland, Norway and Liechtenstein.

On 15 March 2024, Lundbeck announced the advancement of the clinical development of Lu AG09222 for migraine prevention with the initiation of *PROCEED*, a randomized, double-blind, phase IIb, dose-finding trial to assess efficacy and safety of multiple subcutaneously administered doses. The *PROCEED* trial builds on the positive results of the *HOPE* phase IIa Proof-of-Concept trial demonstrating efficacy of intravenously administered Lu AG09222 in migraine prevention.

On 5 March 2024, Lundbeck announced clinical data from the *AMULET* phase II, double-blind, randomized trial of Lu AF82422 in MSA at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD 2024). Based on the encouraging *AMULET* trial outcomes, Lundbeck plans to initiate a phase III study, following further dialogue with health authorities.

Lundbeck announced key leadership changes on 23 February 2024. Michala Fischer-Hansen joined as Executive Vice President and Head of Europe & International Markets. Additionally, Tine Østergaard Hansen and Dianne Hol were appointed Senior Vice President of Corporate Communication & Public Affairs and Executive Vice President of People & Organization, respectively. Furthermore, on 13 May 2024, Lundbeck announced the appointment of Maria Alfaiate as Executive Vice President Commercial and Corporate Strategy.

Financial guidance 2024 maintained

On 7 February 2024, Lundbeck communicated the financial guidance for 2024 focusing on revenue performance and adjusted EBITDA at CER.

The revenue growth is expected to be 7% to 10% at CER when compared to revenue of the prior year excluding the effect from hedging. The adjusted EBITDA growth is expected to be 10% to 16% at CER when compared to adjusted EBITDA of the prior year excluding effects from hedging. Further details are available in section 2.7 *Outlook*.

Conference call

Today at 13.00 CET, Lundbeck will be hosting a conference call for the financial community. You can find dial-ins and a link for webcast online at www.lundbeck.com under the Investor section.

CONTENT

1 FINANCIAL HIGHLIGHTS

For the three months ended 31 March

DKK million	Q1 2024	Q1 2023	*Change (CER)*[1]	*Change (DKK)*
Revenue	**5,288**	**5,044**	***7%***	***5%***
Gross profit	**4,279**	**4,003**	***9%***	***7%***
Gross margin	*80.9%*	*79.4%*		
Adjusted gross profit[2]	4,700	4,568	*5%*	*3%*
Adjusted gross margin	*88.9%*	*90.6%*		
Sales and distribution costs	1,789	1,673	*9%*	*7%*
S&D ratio	*33.8%*	*33.2%*		
Administrative expenses	259	258	*2%*	*0%*
Administrative expenses ratio	*4.9%*	*5.1%*		
Research and development costs	953	839	*14%*	*14%*
R&D ratio	*18.0%*	*16.6%*		
EBIT (profit from operations)	1,278	1,233	*9%*	*4%*
EBIT margin	*24.2%*	*24.4%*		
EBITDA[3]	**1,746**	**1,744**	***4%***	***0%***
EBITDA margin	*33.0%*	*34.6%*		
Adjusted EBITDA[4]	**1,746**	**1,845**	***(2%)***	***(5%)***
Adjusted EBITDA margin	*33.0%*	*36.6%*		
Net financials, (income)/expenses	(29)	83	-	*135%*
Profit before tax	1,307	1,150	-	*14%*
Income taxes	301	270	-	*11%*
Effective tax rate (reported)	*23.0%*	*23.5%*		
Net profit	**1,006**	**880**	**-**	***14%***
Adjusted net profit	1,371	1,355	-	*1%*

Other key numbers				
Assets	37,852	36,624	-	*3%*
Equity	22,435	20,980	-	*7%*
Cash flows from operating and investing activities (free cash flow)	867	301	-	*188%*
Net cash flow for the period	107	(654)	-	*116%*
Return on invested capital – rolling four quarters	*11.0%*	*10.5%*		
Net debt/EBITDA – rolling four quarters	(0.2)	0.5	-	*(140%)*
Number of shares for the calculation of EPS (millions)	992.1	992.9	-	*0%*
Earnings per share, basic (EPS) (DKK)	1.01	0.89	-	*13%*
Adjusted earnings per share, basic (DKK)	1.38	1.36	-	*1%*

[1] Change at CER (Constant Exchange Rates) does not include effects from hedging.
[2] Adjusted gross profit is the gross profit excluding depreciation and amortization and other adjustments linked to sales.
[3] EBITDA refers to Earnings Before Interest, Taxes, Depreciation and Amortization.
[4] EBITDA refers to Earnings Before Interest, Taxes, Depreciation and Amortization. Adjusted EBITDA is defined as EBITDA adjusted by certain items, for details see section 4 *Notes*, note 3 *Adjusted EBITDA*.

2 BUSINESS PERFORMANCE

2.1 REVENUE BY PRODUCT

Revenue reached DKK 5,288 million representing a growth of 7% CER (+5% DKK). The revenue growth is driven by the strong performance of the strategic brands reaching DKK 3,759 million, representing a growth of 17% CER (+15% DKK) and equivalent to 71% of total revenue. The largest markets for the strategic brands are the U.S., Canada, Spain, Italy and France.

DKK million	Q1 2024	Q1 2023	*Growth (CER)*	*Growth (DKK)*
Brintellix®/Trintellix®	1,168	1,077	*11%*	*8%*
Rexulti®	1,115	1,060	*7%*	*5%*
Abilify Maintena®/Asimtufii	859	785	*10%*	*9%*
Vyepti®	617	351	*79%*	*76%*
Strategic brands	**3,759**	**3,273**	***17%***	***15%***
Cipralex®/Lexapro®	618	664	*1%*	*(7%)*
Other pharmaceuticals	850	1,073	*(18%)*	*(21%)*
Mature brands	**1,468**	**1,737**	***(11%)***	***(15%)***
Other revenue	70	63	*11%*	*11%*
Total revenue before hedging	**5,297**	**5,073**	***7%***	***4%***
Effects from hedging	(9)	(29)		
Total revenue	**5,288**	**5,044**	***7%***	***5%***

Strategic brands

Brintellix®/Trintellix® (vortioxetine) is approved for the treatment of MDD. Revenue reached DKK 1,168 million representing a growth of 11% CER (+8% DKK), contributed by all regions, with strong performance in Europe, driven by higher demand, with solid contribution from Spain. In the U.S., growth was driven by price increase, offset by lower demand. The continued higher sales in Japan also contributed to the growth in International Markets. The revenue distribution by region was 31%, 36% and 33% in the U.S., Europe and International Markets, respectively. The largest markets for the product are the U.S., Spain, Canada, Italy and Brazil.

Rexulti® (brexpiprazole) is approved as an adjunctive therapy for the treatment of adults with major depressive disorder (MDD) and as a treatment for adults with schizophrenia in markets such as the U.S., Canada and Brazil. Further, it is approved for the treatment of agitation associated with dementia due to Alzheimer's disease (AADAD) in the U.S. since May 2023. Following the approval, the brand has seen a continued strong growth in latest claims data especially led by the strong uptake in long-term-care facilities. In addition, AADAD has been approved in Canada and has been filed in certain other countries. In Australia and Europe, the product is approved for schizophrenia. Revenue reached DKK 1,115 million representing a growth of 7% CER (+5% DKK), contributed by all the regions. In the U.S., sales performance was mainly driven by continued growth following the AADAD approval, however growth for the brand in the U.S. has been negatively impacted by a temporary suspension of Direct-to-consumer (DTC) spend in MDD since November 2023. The activity has restarted in February 2024. In Europe and International Markets, sales growth was driven by higher demand. The revenue distribution by region was 91%, 2% and 7% in the U.S., Europe and International Markets, respectively. The largest markets are the U.S., Brazil, Canada, Australia and Mexico.

Abilify Maintena® (aripiprazole) is approved for the treatment of schizophrenia in Europe and for both schizophrenia and bipolar I disorder in the U.S., Canada and Australia as a once-monthly injection. In March 2024, the European Commission (EC) approved Abilify Maintena® 960 mg (aripiprazole) as a once-every-two-months long-acting injectable (LAI) formulation for the maintenance treatment of schizophrenia in adult patients stabilized with aripiprazole. This applies to all EU member states, as well as Iceland, Norway and Liechtenstein. In April 2023, FDA approved a New Drug Application (NDA)

for aripiprazole as an every-two-months injection branded as **Abilify Asimtufii®** which was launched in the U.S. in June 2023. Revenue for Abilify Maintena® and Abilify Asimtufii® reached DKK 859 million representing a growth of 10% CER (+9% DKK) contributed by all regions. In the U.S., sales growth was mainly driven by higher demand for Abilify Asimtufii®. In Europe, sales growth was driven by higher demand. The continued demand uptake in Canada also contributed strongly to International Markets sales growth. The revenue distribution by region was 35%, 47% and 18% in the U.S., Europe and International Markets, respectively. The largest markets are the U.S., Spain, Canada, Australia and Italy.

Vyepti® (eptinezumab) is approved as a preventive treatment of migraine in adults. Vyepti® delivered significant growth in the first quarter of 2024 and revenue reached DKK 617 million following an increase of 79% CER (+76% DKK) across all the regions. In the U.S., Vyepti® sales growth was mainly driven by prescription volume growth and market share gains, reflecting the continued demand uptake of Vyepti®. In Europe and International Markets, sales growth was driven by market share gains as part of the continued demand uptake, with strong performance in Canada as well as the launches across the world. Vyepti® was initially launched in April 2020 in the U.S. and has since been launched in around 25 markets in total. In October 2023, Vyepti® received public formulary coverage from certain provinces in Canada. Combined, this coverage allows more than 80% of eligible Canadian patients living with migraine to have access to Vyepti®. The revenue distribution by region was 88%, 7% and 5% in the U.S., Europe and International Markets, respectively.

Mature brands

Cipralex®/Lexapro® (escitalopram) is approved for the treatment of MDD. Revenue reached DKK 618 million representing a growth of 1% CER (-7% DKK) mainly due to strong performance in-market sales in China and price increase in Turkey due to inflation, partially offset by continued erosion in Japan and Switzerland. The revenue distribution by region was 73% and 27% in International Markets and Europe, respectively. The largest markets are China, Saudi Arabia, Brazil, South Korea and Italy.

Revenue from **Other pharmaceuticals**, which comprises the remainder of Lundbeck's products, reached DKK 850 million representing a decline of 18% CER (-21% DKK), mainly due to lower sales of certain mature products such as Northera®, Sabril® and Deanxit®. As of 1 January 2024, Sabril® is being reported together with Other pharmaceuticals, comparative figures for 2023 have been adjusted accordingly. The largest markets for Other pharmaceuticals are the U.S, China, France, South Korea and Thailand.

2.2 REVENUE BY GEOGRAPHICAL AREA

DKK million	Q1 2024	Q1 2023	*Growth (CER)*	*Growth (DKK)*
United States				
Rexulti®	1,018	979	*6%*	*4%*
Vyepti®	544	328	*69%*	*66%*
Trintellix®	358	338	*7%*	*6%*
Abilify Maintena®/Asimtufii	301	282	*9%*	*7%*
Strategic brands	**2,221**	**1,927**	***17%***	***15%***
Mature brands	277	410	*(31%)*	*(32%)*
Revenue – United States	**2,498**	**2,337**	***9%***	***7%***
Europe				
Brintellix®	423	371	*16%*	*14%*
Abilify Maintena®	400	355	*12%*	*13%*
Vyepti®	45	12	*275%*	*275%*
Rexulti®	18	13	*38%*	*38%*
Strategic brands	**886**	**751**	***19%***	***18%***
Mature brands	362	423	*(9%)*	*(14%)*
Revenue – Europe	**1,248**	**1,174**	***9%***	***6%***
International Markets				
Brintellix®/Trintellix®	387	368	*10%*	*5%*
Abilify Maintena®	158	148	*10%*	*7%*
Rexulti®	79	68	*21%*	*16%*
Vyepti®	28	11	*155%*	*155%*
Strategic brands	**652**	**595**	***14%***	***10%***
Mature brands	829	904	*(2%)*	*(8%)*
Revenue – International Markets	**1,481**	**1,499**	***4%***	***(1%)***
Other revenue	70	63	*11%*	*11%*
Total revenue before hedging	**5,297**	**5,073**	***7%***	***4%***
Effects from hedging	(9)	(29)		
Total revenue	**5,288**	**5,044**	***7%***	***5%***

Lundbeck's largest markets are the U.S., China, Canada, Spain and Italy.

United States revenue reached DKK 2,498 million representing a growth of 9% CER (+7% DKK). The strategic brands reached DKK 2,221 million increasing by 17% CER (+15% DKK), representing 89% of the revenue. The revenue growth is mainly driven by the continued demand uptake of Vyepti®. Additionally, strategic brands were positively impacted by continued growth since the AADAD approval. Mature brands such as Northera®, Onfi® and Sabril® have been impacted by lower sales.

Europe revenue reached DKK 1,248 million representing a growth of 9% CER (+6% DKK). The strategic brands reached DKK 886 million increasing 19% CER (+18% DKK), representing 71% of revenue. The revenue growth is mainly driven by higher demand for Brintellix® and Abilify Maintena® as well as continued demand uptake of Vyepti®. Mature brands have been impacted by continued price pressure as well as continued erosion of certain brands such as Cipralex® in Switzerland, Cipramil® and Cisordinol®. The largest markets in Europe are Spain, Italy, France, Switzerland and Greece.

International Markets comprises all Lundbeck's markets outside the U.S. and Europe. Revenue reached DKK 1,481 million representing a growth of 4% CER (-1% DKK). The strategic brands reached DKK 652 million increasing by 14% CER (+10% DKK), representing 44% of revenue. The revenue growth is mainly driven by higher demand across all four brands. Mature brands have been impacted by ongoing erosion of certain brands such as Lexapro®

in Japan following the entry of generic competition since the end of 2022 as well as the erosion of Deanxit® in China. The biggest markets are China, Canada, Brazil, Saudi Arabia and Australia. China and Canada constitute approximately 41% of the regional revenue.

Effects from hedging
Lundbeck hedges a significant part of the currency risk for a period of 12 – 18 months. Hedging had a negative impact of DKK 9 million in the first quarter of 2024, compared to a negative impact of DKK 29 million in the same period last year.

2.3 GROSS PROFIT

DKK million	Q1 2024	Q1 2023	*Change (CER)*	*Change (DKK)*
Revenue	**5,288**	**5,044**	***7%***	***5%***
Cost of sales	1,009	1,041	*0%*	*(3%)*
thereof adjustments	-	101	-	-
thereof amortization of product rights	368	404	*(8%)*	*(9%)*
thereof depreciation/amortization	53	60	*(12%)*	*(12%)*
Gross profit	**4,279**	**4,003**	***9%***	***7%***
Gross margin (%)	*80.9%*	*79.4%*		
Adjusted gross profit	**4,700**	**4,568**	***5%***	***3%***
Adjusted gross margin (%)	*88.9%*	*90.6%*		

Cost of sales reached DKK 1,009 million and remained unchanged at CER (-3% DKK) mainly driven by higher sales, offset by lower amortization due to fully amortized product rights in the first quarter of 2024. The first quarter of 2023 was impacted by the negative effect of Vyepti® inventory obsolescence of DKK 101 million and a favourable effect from quarterly fluctuations in stock valuation.

Gross profit reached DKK 4,279 million, increasing by 9% CER (+7% DKK). The gross margin was 80.9% representing an increase of 1.5 percentage points. The increase was mainly driven by higher sales as well as the effect of lower amortization costs in the first quarter of 2024. The first quarter of 2023 was impacted by the negative effect of Vyepti® inventory obsolescence and a favourable effect from quarterly fluctuations in stock valuation.

Adjusted gross profit is the gross profit excluding depreciation and amortization and other adjustments linked to sales. The **adjusted gross margin** was 88.9% representing a decrease of 1.7 percentage points. The decrease reflects mainly higher sales and the effect of a favourable effect from quarterly fluctuations in stock valuation.

Amortization of product rights was DKK 368 million, decreasing by 8% CER (-9% DKK).

2.4 EBIT AND ADJUSTED EBITDA

DKK million	Q1 2024	Q1 2023	*Change (CER)*	*Change (DKK)*
Revenue	**5,288**	**5,044**	***7%***	***5%***
Gross profit	**4,279**	**4,003**	***9%***	***7%***
thereof adjustments	-	101	-	-
thereof depreciation/amortization	421	464	*(9%)*	*(9%)*
Sales and distribution costs	1,789	1,673	*9%*	*7%*
thereof depreciation/amortization	22	24	*(8%)*	*(8%)*
S&D-ratio	*33.8%*	*33.2%*		
Administrative expenses	259	258	*2%*	*0%*
thereof depreciation/amortization	5	5	*0%*	*0%*
Administrative expenses ratio	*4.9%*	*5.1%*		
Research and development costs	953	839	*14%*	*14%*
thereof depreciation/amortization	20	18	*11%*	*11%*
R&D-ratio	*18.0%*	*16.6%*		
Total operating expenses	**3,001**	**2,770**	***10%***	***8%***
OPEX-ratio	*56.8%*	*54.9%*		
EBIT (profit from operations)	**1,278**	**1,233**	***9%***	***4%***
Depreciation/amortization	468	511	*(8%)*	*(8%)*
EBITDA	**1,746**	**1,744**	***4%***	***0%***
EBITDA margin (%)	*33.0%*	*34.6%*		
Other adjustments	-	101	-	-
Adjusted EBITDA	**1,746**	**1,845**	***(2%)***	***(5%)***
Adjusted EBITDA margin (%)	*33.0%*	*36.6%*		

Total operating expenses (OPEX) reached DKK 3,001 million corresponding to an increase of 10% CER (+8% DKK) mainly driven by higher sales and distribution costs as well as R&D costs. The OPEX-ratio increased by 1.9 percentage points.

Sales and distribution costs reached DKK 1,789 million corresponding to an increase of 9% CER (+7% DKK) reflecting the continued investments in sales and promotion activities in strategic brands such as Rexulti® and Vyepti® in the U.S. and the global roll-out of Vyepti®.

Sales and distribution costs corresponded to 33.8% of revenue, representing an increase of 0.6 percentage points.

Administrative expenses reached DKK 259 million, increasing by 2% CER (0% DKK) corresponding to 4.9% of total revenue.

Research and development costs reached DKK 953 million with an R&D ratio of 18.0%. Higher R&D costs of 14% CER (+14% DKK) reflects mainly investments in Lundbeck's progressing pipeline encompassing eight projects. Further details are available in section 2.8 *Lundbeck's development portfolio*. The main development in R&D costs comes from the progression of the phase II pipeline with initiation of a phase IIb dose finding trial for anti-PACAP and phase III preparations for Lu AF82422 (anti-alpha-synuclein mAb).

EBIT reached DKK 1,278 million, increasing by 9% CER (+4% DKK) reflecting the operating leverage effect of higher revenue and lower product rights amortization, offset by higher operating expenses regarding investments in sales and distribution and R&D costs. Furthermore, EBIT for the first quarter of 2023 was negatively affected by the recognition of a provision of DKK 101 million for Vyepti® inventory obsolescence and a favourable effect from quarterly fluctuations in stock valuation.

Amortization of product rights amounted to DKK 368 million corresponding to a decrease of 8% CER

(-9% DKK). **Total amortization, depreciation and impairment losses** reached DKK 468 million representing a decrease of 8% CER (-8% DKK) mainly driven by a decrease in the amortization recognized in the first quarter of 2024 due to fully amortized product rights.

Adjusted EBITDA reached DKK 1,746 million representing a decline of 2% CER (-5% DKK) reflecting EBIT and EBITDA development. Excluding the favourable effect from quarterly fluctuations in stock valuation, the underlying growth in the adjusted EBITDA was 6% CER, constituting an adjusted EBITDA margin decrease of 0.6 percentage points.

2.5 NET PROFIT AND ADJUSTED EPS

DKK million	Q1 2024	Q1 2023	*Change (DKK)*
EBIT (profit from operations)	**1,278**	**1,233**	***4%***
Net financials, (income)/expenses	(29)	83	*135%*
Profit before tax	1,307	1,150	*14%*
Net profit	**1,006**	**880**	***14%***
thereof other adjustments	-	101	-
thereof depreciation/amortization	468	511	*(8%)*
thereof tax on adjustments	103	137	*(25%)*
EPS (DKK)	1.01	0.89	*13%*
Adjusted net profit	**1,371**	**1,355**	***1%***
Adjusted EPS (DKK)	1.38	1.36	*1%*

Net profit

Net financial expenses amounted to an income of DKK 29 million equivalent to an increase of 135% due to the positive development in interest expenses, favourable currency impact as well as lower interest-bearing debt.

The **effective tax rate** for the first quarter of 2024 was 23.0% (23.5% for the first quarter of 2023). The tax rate is in line with the full-year expectation.

Net profit reached DKK 1,006 million corresponding to a growth of 14%.

Adjusted net profit and EPS

Adjusted net profit is the net profit excluding depreciation and amortization and other adjustments, net of taxes. Adjusted net profit reached DKK 1,371 million, representing an increase of 1%. The adjustments are mainly related to amortization of product rights in the first quarter of 2024.

Adjusted EPS was DKK 1.38 corresponding to an increase of 1%.

2.6 CASH FLOW AND BALANCE SHEET

DKK million	Q1 2024	Q1 2023
Profit from operations (EBIT)	**1,278**	**1,233**
Cash flows from operating activities	961	378
Cash flows from investing activities	(94)	(77)
Cash flows from operating and investing activities (free cash flow)	**867**	**301**
Cash flows from financing activities	(760)	(955)
Net cash flow for the period	**107**	**(654)**

Cash flows from operating activities amounted to an inflow of DKK 961 million compared to an inflow of DKK 378 million in the first quarter of 2023 mainly driven by a combination of higher EBIT, lower inventory build-up and lower short-term liabilities due

to Rexulti® milestone paid-out in the first quarter of 2023.

Lundbeck's **net cash flows from investing activities** were an outflow of DKK 94 million compared to an outflow of DKK 77 million in the first quarter of 2023. The investing activities mainly include capital expenditures in property, plant and equipment as well as intangible assets.

Lundbeck's **net cash flows from financing activities** were an outflow of DKK 760 million compared to an outflow of DKK 955 million in the first quarter of 2023 mainly relate to repayment of debt, offset by higher dividend paid in March 2024.

The net cash inflow reached DKK 107 million compared to an outflow of DKK 654 million in the first quarter of 2023.

Net debt has decreased from DKK 2,491 million at the end of March 2023 to **net cash** of DKK 799 million at the end of March 2024. Net debt/EBITDA ratio is -0.2x at the end of March 2024 compared to 0.5x at the end of March 2023. **Interest-bearing debt** was DKK 4,314 million at the end of March 2024 compared to DKK 5,373 million at the end of March 2023.

On 31 March 2024, Lundbeck's **total assets** amounted to DKK 37,852 million compared to DKK 37,407 million at the end of 2023.

On 31 March 2024, Lundbeck's **equity** amounted to DKK 22,435 million.

2.7 OUTLOOK

Financial guidance 2024

On 7 February 2024, Lundbeck communicated the financial guidance for 2024 focusing on revenue performance and adjusted EBITDA at CER.

Lundbeck maintains its full year guidance for 2024, where revenue is expected to grow 7% to 10% at CER when compared to revenue of the prior year excluding effects from hedging. Assuming the current exchange rates versus DKK, the revenue growth reported in DKK is expected to be around 3 percentage points lower than at CER. Lundbeck expects revenue growth is mainly driven by the demand of the strategic brands.

The guidance range reflects continued strong growth of Vyepti® in the U.S. and the continued global roll-out. Additionally, the guidance expects robust growth of Rexulti® following AADAD indication in the U.S. Furthermore, the guidance range comprises growth of Brintellix® in Europe and International Markets as well as slight growth for Abilify Maintena®/Asimtufii in the U.S.

For the financial guidance for 2024, published in February 2024, Lundbeck expected the most relevant generic erosion impacts for the year coming from brands such as Cipralex®/Lexapro®, Deanxit® and Sabril®. For the coming quarters, Lundbeck expects slightly growth to Cipralex®/Lexapro® and Deanxit® as well as lower level of erosion for Sabril® despite higher than expected generic erosion from Northera® and Xenazine®.

Adjusted EBITDA is expected to grow 10% to 16% at CER in 2024 when compared to adjusted EBITDA of the prior year excluding effects from hedging. Assuming the current exchange rates versus DKK, the adjusted EBITDA growth reported in DKK is expected to be around 8 percentage points lower than at CER. Lundbeck expects higher R&D costs driven by the progression of the pipeline, higher sales and distribution costs due to increased Vyepti® and Rexulti® promotion activities.

Lundbeck mainly carries foreign currency risk in USD, CNY, CAD, BRL and AUD. Other relevant financial information for FY 2024 at reported rates presented below has been monitored and reviewed considering actual exchange rates for the period already incurred and the following estimated exchanges rates for the remaining period of the year: USD/DKK (6.90); CNY/DKK (0.95); CAD/DKK (5.09); BRL/DKK (1.38); AUD/DKK (4.49).

All the above expectations are based on assumptions that the global or regional macroeconomic and political environment will not significantly change business conditions for Lundbeck during 2024, including the impact of any potential material business development activities and the potential implications.

In the table below, the expectations and additional relevant information have been summarized.

Financial guidance for 2024	As of 7 February 2024
Total revenue growth at CER	7% to 10%
Adjusted EBITDA growth at CER	10% to 16%
Other relevant financial information for FY 2024 at reported rates	
Total revenue (IFRS) growth[1]	Around 3 percentage points lower than at CER
Adjusted EBITDA growth[1]	Around 8 percentage points lower than at CER
Adjusted gross margin[2]	88% to 89%
R&D costs	DKK 3.9 to 4.1 billion
Depreciation & amortization	DKK 1.8 to 2.0 billion
Net financials, expenses	DKK 0 to 50 million
Effects from hedging	DKK -130 to -155 million
Effective tax rate	22% to 24%
Net cash/(net debt)[3]	DKK 4.2 to 4.7 billion

[1] Includes effects from hedging and exchange rate impact.
[2] Adjusted gross margin is the gross margin excluding depreciation and amortization and other adjustments linked to sales.
[3] Net cash/(net debt) is defined as Interest-bearing debt, cash, cash equivalents and securities, net.

Revenue at CER

DKK million	Q1 2024
Total revenue (IFRS)	**5,288**
Effects from hedging	(9)
Total revenue (IFRS) before hedging	**5,297**
Effects from exchange rate	(154)
Total revenue at CER	**5,451**
Increase/(decrease) in total revenue	5%
Increase/(decrease) in total revenue at CER[1]	7%

[1] Total revenue at CER for the period divided by total revenue (IFRS) before hedging for the comparative period.

Adjusted EBITDA at CER

DKK million	Q1 2024
Adjusted EBITDA	**1,746**
Effects from hedging	(9)
Adjusted EBITDA before hedging	**1,755**
Effects from exchange rate	(87)
Adjusted EBITDA at CER	**1,842**
Increase/(decrease) in adjusted EBITDA	(5%)
Increase/(decrease) in adjusted EBITDA at CER[1]	(2%)

[1] Adjusted EBITDA at CER for the period divided by adjusted EBITDA before hedging for the comparative period.

Mid-term targets

Lundbeck's mid-term targets communicated in February 2023 remain unchanged. Lundbeck is in a period with limited impact from major regional losses of exclusivity and anticipates solid growth of its strategic brands.

In 2024 and 2025, Lundbeck plans targeted investments behind the potential blockbuster opportunity for Rexulti® in the treatment of AADAD. Based on organic growth, we expect revenue to show a mid-single digit compound annual growth rate (CAGR) over the next three years.

At the same time, we remain focused on driving efficiencies and being prudent in our spending. Based on these assumptions, we target an adjusted EBITDA-margin of 30-32% for the current business, excluding any material business development activities, by the end of the mid-term period (2026).

Forward-looking statements

Forward-looking statements are subject to risks, uncertainties, and inaccurate assumptions. This may cause actual results to differ materially from expectations. Various factors may affect future results, including interest rates and exchange rate fluctuations, delay or failure of development projects,

production problems, unexpected contract breaches or terminations, governance-mandated or market-driven price decreases for products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws, and unexpected growth in expenses.

2.8 LUNDBECK'S DEVELOPMENT PORTFOLIO

Lundbeck is developing several new and promising medicines for the treatment of brain diseases. The pipeline developments are summarized below.

Project	Area	Phase I	Phase II	Phase III	Filing/ Launch
Hormonal / neuropeptide signalling:					
Eptinezumab (anti-CGRP)[1]	Migraine prevention			*SUN-studies*[2]	
	Cluster headache		*CHRONICLE*[3]	*ALLEVIATE*	
Lu AG09222 (anti-PACAP mAb)[4]	Migraine prevention		*PROCEED*		
Lu AG13909 (anti-ACTH mAb)[5]	Neuro-hormonal dysfunctions				
Circuitry / neuronal biology:					
Brexpiprazole[6]	PTSD				
MAGLi programs[7]	Neurology				
Lu AF28996 (D_1/D_2 agonist)	Parkinson's disease				
Protein aggregation, folding and clearance:					
Lu AF82422 (anti-α-synuclein mAb)	Multiple system atrophy		*AMULET*		
Neuroinflammation / neuroimmunology:					
Lu AG22515 (anti-CD40L blocker)	Neurology				

[1] CGRP: Calcitonin gene-related peptide. [2] Two phase III clinical trials, supporting registration in Asia, including China and Japan: *SUNRISE*, and *SUNSET* trials. [3] Long-term safety study. [4] PACAP: Pituitary adenylate cyclase activating peptide. [5] Adrenocorticotropic hormone. [6] Acts as a partial agonist at 5-HT_{1A} and dopamine D_2 receptors at similar potency, and an antagonist at 5-HT_{2A} and noradrenaline alpha1B/2C receptors. [7] Monoacylglycerol lipase inhibitor ("MAGlipase").

Hormonal / neuropeptide signalling

Lu AG09222 – phase II

Lu AG09222 represents a potential new therapeutic option for the treatment of migraine, which, unlike the recently available calcitonin gene-related peptide (CGRP) migraine treatment drug class, targets pituitary adenylate cyclase-activating polypeptide (anti-PACAP mAb). PACAP and its receptors are broadly expressed in the nervous systems and inflammatory cells. By interfering with the PACAP signalling there is a potential to affect multiple symptoms of headache disorders.

Lundbeck has initiated the *PROCEED* trial, a phase IIb trial with subcutaneously administered Lu AG09222 that builds on the positive results of the *HOPE* trial.

PROCEED is an interventional, randomized, double-blind, parallel-group, placebo-controlled, dose-finding phase IIb trial that will be conducted in Europe, Japan and the U.S. It assesses four different doses of Lu AG09222 versus placebo, administered subcutaneously once monthly for three months. The trial is intended to establish the optimal dose for future global pivotal trials designed to confirm the efficacy and safety of Lu AG09222 as a migraine preventive treatment. *PROCEED* is planned to enrol approximately 498 patients and will assess the efficacy, safety and tolerability of Lu AG09222. The target population for this trial is defined as patients diagnosed with migraine as outlined in the International Classification of Headache Disorders Third Edition (ICHD-3) and with failure to 2-4 different preventive migraine medications in the past 10 years. Study completion is expected in H2 2025.

Circuitry / neuronal biology

Brexpiprazole – phase III in Post-Traumatic Stress Disorder (PTSD)

On 7 September 2023, Lundbeck announced topline results from two phase III trials of brexpiprazole as combination therapy with sertraline for the treatment of Post-Traumatic Stress Disorder in adults, namely the flexible dose trial 071 (NCT04124614) and the fixed dose trial 072 (NCT04174170). The flexible dose trial met its primary endpoint, while the fixed dose phase III trial missed its primary endpoint. The safety and tolerability results were consistent with the profile of brexpiprazole as observed in the clinical trials for schizophrenia, AADAD and adjunctive treatment of MDD.

On 9 April 2024 Lundbeck submitted a supplemental New Drug Application (sNDA) for U.S. Food and Drug Administration (FDA) review of brexpiprazole as

combination therapy with sertraline for the treatment of Post-Traumatic Stress Disorder (PTSD) in adults.

FDA validation of the submission dossier, prior to FDA's decision whether to proceed with a full review, is expected in June 2024 including information on whether FDA assigns priority or standard review.

The sNDA submission is based on the two recently completed clinical phase III trials and a phase trial, which all investigated the treatment of PTSD in adults treated with brexpiprazole in combination with sertraline versus sertraline plus placebo. Detailed data from all three trials will be presented at the American Society of Clinical Psychopharmacology (ASCP) 28 – 31 May 2024 in Miami, Florida.

Protein aggregation, folding and clearance

Lu AF82422 – phase II

Lu AF82422 is a monoclonal antibody (mAb) targeting the pathological form of the protein alpha-synuclein that is believed to play a pivotal role in the development and progression of neurodegenerative diseases such as multiple system atrophy (MSA), Parkinson's disease (PD), and other synucleinopathies. By targeting pathological alpha-synuclein with an antibody that will inhibit aggregation and potentially clear pathological alpha-synuclein from the brain, the project aims to demonstrate delay of disease progression and therapeutic effect on disease burden and function. A phase II randomized, double-blind, placebo-controlled exploratory proof-of-concept (PoC) trial (*AMULET*) testing Lu AF82422 in MSA patients was initiated in November 2021 (NCT05104476) in the U.S and Japan.

In January 2024, Lundbeck announced results of the *AMULET* PoC trial. The trial included 61 MSA patients randomized 2:1 (40 on Lu AF82422 versus 21 on placebo) and treated for 48-72 weeks. The primary endpoint in the trial measured slowing of progression of MSA as measured by Unified Multiple System Atrophy Rating Scale (UMSARS) Total Score Part I and II, while the key secondary endpoints included Modified UMSARS Part I as well as several other clinical outcome measures and biomarkers. The primary statistical approach consisted of a Bayesian slope analysis. While the trial did not reach statistical significance on its primary endpoint, a trend towards slowing MSA disease progression was observed in the group exposed to Lu AF82422 compared to the placebo group, and additional signals of efficacy were observed across other clinical and biomarker endpoints. Lu AF82422 was generally well tolerated. Lundbeck plans to initiate a phase III study, following further dialogue with health authorities.

Orphan drug designation for MSA was granted by EMA in April 2021 and SAKIGAKE pioneering drug designation was granted by the Japanese Health Authorities in March 2023. In April 2024, Lundbeck also obtained orphan drug designation for the Lu AF82422 in MSA by the FDA.

2.9 SUSTAINABILITY UPDATE

Lundbeck's sustainability strategy aims to ensure that we mitigate our most significant sustainability risks and adverse impacts, while acting on the opportunities to make a positive impact on the environment, patients and the communities.

In this sustainability update, progress is presented for Environmental, Social and Governance matters supported by key performance metrics.

ENVIRONMENTAL PERFORMANCE

Category[1]	Q1 2024	Q1 2023[2]	*Change (%)*
Scope 1 GHG emissions (Tonne CO_{2e})	5,983	5,917	*1%*
Scope 2 GHG emissions (Market Based) (Tonne CO_{2e})	1,122	974	*15%*
Scope 1+2 GHGs (Tonne CO2e)	7,105	6,891	*3%*
Energy consumption (MWh)	32,411	30,736	*5%*

[1] See Lundbeck Sustainability Report 2023 for accounting policies and definitions.
[2] All comparative figures were updated to reflect changes in estimates.

Climate Action

Lundbeck is committed to protecting the environment and believes that a healthy environment is a precondition for good health and wellbeing. Lundbeck has targets to reduce its total carbon footprint across its own operations, supply chain, and distribution.

In the quarter of 2024, **Scope 1 + 2 GHG emissions** increased by 3%, compared to the first quarter of 2023. **Scope 1** and **Scope 2 emissions** increased by 1% and 15%, respectively, due to the commencement of operation of a new production unit at our production site in Padova (Italy).

Despite the increased emissions in the first quarter of 2024, Lundbeck remains on track to meet its climate targets, as the planned actions in the low carbon transition plan will come into effect.

Other topics

In 2022, traces of PFAS (per- and polyfluoroalkyl substances) were found at Lundbeck's Lumsås production facility. The pollution stems from the use of fire-retardant foam containing the PFAS type PFOS (perfluorooctane sulfonate) until 2011, in compliance with national fire safety and environmental regulations at the time. Lundbeck switched to a supply of PFOS-free fire-retardant foam more than 11 years ago.

Since the pollution was detected, Lundbeck has been engaged in a close dialogue with the Danish Environmental Protection Agency (EPA) and local authorities regarding the mapping and remediation possibilities of the pollution.

Lundbeck received an order from the EPA with the technical specification for environmental remediation of one area of the site. The order requires the installation of a pump and treat solution for subsoil water. Lundbeck continues a close dialogue with the authorities and affected stakeholders and keep an eye on the development of technologies to efficiently clean PFAS pollution from the contaminated soil and water.

SOCIAL PERFORMANCE

Category[1]	Q1 2024	Q1 2023	*Change*[2]
Gender balance (women % in senior management)	32.9%	34.7%	*(1.8)*

[1] See Lundbeck Sustainability Report 2023 for accounting policies and definitions.
[2] Variation in percentage points.

Diversity, Equity and Inclusion

Lundbeck is a diverse company determined to build an inclusive high-performance culture, where all employees can enrich their professional skills and career paths. We are committed to fostering a diverse workforce and an inclusive culture of belonging where everybody can thrive, be their authentic selves, and perform at their best. This includes taking action on gender equality, and Lundbeck has a target to increase the share of the underrepresented gender at senior management level year-on-year.

In the first quarter of 2024, the **Gender balance in senior management** decreased to 32.9% women, compared to 34.7% in the first quarter of 2023. The decrease is due to changes in the Executive Management in the end of 2023 and beginning of 2024.

Access to Brain Health

Lundbeck has a responsibility to support disease awareness and help address the societal burden thereof. Lundbeck has provided the Red Cross with a grant of DKK 5 million, which will be used to expand mental health support activities in Ukraine, such as its psychological first aid, creating child-friendly spaces and providing training for their volunteers and staff.

GOVERNANCE PERFORMANCE

Category[1]	Q1 2024	Q1 2023	*Change (%)*
Due Diligence screenings of Suppliers and Third Parties (Number)	75	52	*44%*

[1] See Lundbeck Sustainability Report 2023 for accounting policies and definitions.

Responsible Business Conduct

Responsible business conduct is crucial to Lundbeck as a global pharmaceutical company. It translates into how Lundbeck upholds stakeholder integrity and minimizes the risk of financial repercussions.

The number of **Due Diligence screenings** conducted in the first quarter of 2024 increased by 44%, compared to the first quarter of 2023. This increase is due to continued growing awareness across the organization on the importance of ethical business conduct in the value chain.

2.10 GENERAL CORPORATE MATTERS

Pending legal proceedings

Lundbeck is involved in a number of legal proceedings, including patent disputes and environmental matters, the most significant of which are described below. Some of these involve significant amounts and are subject to considerable uncertainty. Management continuously assesses the risks associated with the legal proceedings, and their likely outcome. It is the opinion of the management that, apart from items recognized in the financial statements, the outcome of these legal proceedings and disputes are not probable or cannot be reliably estimated in terms of amount or timing. Such proceedings may, however, develop over time, and new proceedings may occur, in a way which could have a material impact on the Group's financial position and/or cash flows.

In June 2013, Lundbeck received the European Commission's decision that agreements concluded with four generic competitors concerning citalopram violated competition law. The decision included fining Lundbeck EUR 93.8 million (approximately DKK 700 million). Lundbeck paid and expensed the fine in the third quarter of 2013. In March 2021, the European Court of Justice rejected Lundbeck's final appeal of the European Commission's decision. So-called "follow-on claims" for reimbursement of alleged losses, resulting from violation of competition law, often arise when decisions and fines issued by the European Commission are upheld by the European Court of Justice. The below mentioned "follow-on claims" are ongoing or threatened. Lundbeck disagrees with all claims and intends to defend itself against them.

At the end of first quarter 2023, the UK health authorities served their claim form on Lundbeck and several generic companies, and Lundbeck filed its defence in the third quarter of 2023. In September 2023, a Case Management Conference was held, at which the Competition Appeal Tribunal approved an application for a preliminary issue hearing on whether the claim is time-barred. The preliminary issue hearing was held in April 2024 and a ruling on time-barring is expected in the second or third quarter of 2024.

In late October 2021, Lundbeck received a writ of summons from a German health care company claiming compensation for an alleged loss of profit plus interest payments, allegedly resulting from Lundbeck's conclusion of agreements with two of the four generic competitors, which were comprised by the EU Court of Justice ruling. Lundbeck filed its first defence in May 2022 and the parties have subsequently exchanged additional pleadings. The first instance court hearing has been postponed to the second quarter of 2024. It may take several years before a final conclusion is reached by the German courts.

Lundbeck has been informed about potential claims in other European countries, however, it is still uncertain whether the potential claims will be actively pursued.

In Canada, Lundbeck is involved in three product liability class-action lawsuits relating to Cipralex®/Celexa® (two cases alleging various Celexa-induced birth defects and one case against several SSRI manufacturers (incl. Lundbeck) alleging that SSRI (Celexa®/Lexapro®) induces autism birth defect), three relating to Abilify Maintena® (alleging i.a. failure to warn about compulsive behaviour side effects) and one relating to Rexulti® (also alleging i.a. failure to warn about compulsive behaviour side effects). The cases are in the preliminary stages and as such there is significant uncertainty as to how these lawsuits will be resolved. Lundbeck strongly disagrees with the claims.

In 2018, Lundbeck entered into settlements with three of four generic companies involved in an Australian federal court case, in which Lundbeck was pursuing patent infringement and damages claims over the sale of escitalopram products in Australia. Lundbeck received AUD 51.7 million (DKK 242 million) in 2018. Lundbeck's case against the last of the four generic companies, Sandoz Pty Ltd, went up to the High

Court of Australia, who has now decided that Sandoz Pty Ltd infringed Lundbeck's escitalopram patent between 2009 and 2012. The High Court has now sent the case back to the first instance court for recalculation of the damages awarded to Lundbeck in first instance which amounted to AUD 26.3 million. In the meantime, Lundbeck's appeal of the Australian Patent Office's decision to grant Sandoz a license will be heard on 24 August 2024, and if a license is maintained in any form, the first instance court will have to decide if such a license can have impact on the damage awarded by the High Court.

Lundbeck received a Civil Investigative Demand ("CID") from the U.S. Department of Justice ("DOJ") in March 2020. The CID seeks information regarding the sales, marketing, and promotion (including the promotional speaker program) of Trintellix®. Lundbeck is cooperating with the DOJ.

Lundbeck and Otsuka have received a Paragraph IV certification from Mylan Pharmaceuticals with respect to certain of the patent listed for Abilify Maintena® in the U.S., and Lundbeck and Otsuka have instituted patent infringement proceedings against Mylan and Viatris Inc. The FDA cannot grant marketing authorization in the U.S. to Mylan or Viatris Inc. before the patents expire unless they receive a decision in their favour. The trial has been re-scheduled to start on 17 June 2024 and a District Court decision is currently expected by October 2024. Abilify Maintena® is covered by several U.S. patents relating to specific forms of the active ingredient, formulations, processes, devices, indications and methods of use, which will expire in different years, with the latest patent expiry date in the U.S. being in 2034.

In June 2022 in the U.S., several entities created for the purpose of receiving assignment of claims from payors providing health insurance coverage pursuant to Medicare Parts C and D and Medicaid filed a complaint against Lundbeck and others. The complaint alleges that Lundbeck and the other defendants conspired to increase the unit price and quantity dispensed of Xenazine®. The case was dismissed with prejudice earlier in 2023 and is currently under appeal.

In June 2023 in the U.S., Humana Inc., an insurer, filed a complaint against Lundbeck U.S. legal entities. The complaint alleges that Lundbeck engaged in an illegal kickback scheme to increase the sales and sale price of Lundbeck's Xenazine®. The complaint alleges that Lundbeck's activities targeted Humana Inc. and other private Medicare insurers who were forced to bear the costs of the alleged illegally subsidized drug sales. Lundbeck denies the allegations in the complaint and intends to defend itself.

STATEMENT OF THE BOARD OF DIRECTORS AND THE REGISTERED EXECUTIVE MANAGEMENT

The Board of Directors and the Registered Executive Management have discussed and adopted the financial report of H. Lundbeck A/S for the period 1 January to 31 March 2024. The financial report is presented in accordance with IAS 34 Interim Financial Reporting, as adopted by the EU and additional Danish disclosure requirements for interim financial reports of listed companies.

We consider the accounting policies applied to be appropriate. Accordingly, the financial report gives a true and fair view of the Group's assets, liabilities and financial position as of 31 March 2024, and of the results of the Group's operations and cash flows for the period, which ended on 31 March 2024.

In our opinion, the Management's Review (pages 5-17) gives a true and fair view of activity developments, the Group's general financial position and the results for the period. It also gives a fair view of the significant risks and uncertainty factors that may affect the Group relative to the disclosures in the Annual Report 2023.

The financial report has not been subject to audit or reviewed by the company's independent auditors.

Valby, 15 May 2024

Registered Executive Management

Charl Gerhard Van Zyl President and CEO	Lars Bang Executive Vice President, Product Development & Supply	Joerg Hornstein Executive Vice President, CFO	Per Johan Luthman Executive Vice President, Research & Development

Board of Directors

Lars Søren Rasmussen Chair of the Board	Lene Skole-Sørensen Deputy Chair of the Board	Santiago Arroyo	Jeffrey Berkowitz
Lars Erik Holmqvist	Jakob Riis	Ilse Dorothea Wenzel	Camilla Gram Andersson Employee representative
Hossein Armandi Employee representative	Dorte Clausen Employee representative	Lasse Skibsbye Employee representative	

3 CONDENSED FINANCIAL STATEMENTS

CONDENSED STATEMENT OF PROFIT OR LOSS

DKK million	Q1 2024	Q1 2023
Revenue	5,288	5,044
Cost of sales	1,009	1,041
Gross profit	**4,279**	**4,003**
Sales and distribution costs	1,789	1,673
Administrative expenses	259	258
Research and development costs	953	839
Profit from operations (EBIT)	**1,278**	**1,233**
Net financials, (income)/expenses	(29)	83
Profit before tax	**1,307**	**1,150**
Tax on profit for the period	301	270
Profit for the period	**1,006**	**880**
Earnings per share, basic (EPS) (DKK)	1.01	0.89
Earnings per share, diluted (DEPS) (DKK)	1.01	0.89

STATEMENT OF COMPREHENSIVE INCOME

DKK million	Q1 2024	Q1 2023
Profit for the period	**1,006**	**880**
Actuarial gains/losses	-	-
Tax	-	-
Items that will not be reclassified subsequently to profit or loss	**-**	**-**
Exchange rate gains/losses on investments in foreign subsidiaries	236	(170)
Exchange rate gains/losses on additions to net investments in foreign subsidiaries	(40)	(1)
Hedging of net investments in foreign subsidiaries	-	18
Deferred gains/losses on cash flow hedge, exchange rate	(110)	134
Deferred gains/losses on cash flow hedge, interest rate	-	(9)
Deferred gains/losses on cash flow hedge, price	(17)	(41)
Exchange gains/losses, hedging (transferred to the hedged items)	9	29
Tax	35	(28)
Items that may be reclassified subsequently to profit or loss	**113**	**(68)**
Other comprehensive income	**113**	**(68)**
Comprehensive income	**1,119**	**812**

CONDENSED STATEMENT OF FINANCIAL POSITION

DKK million	31.03.2024	31.12.2023
Assets		
Intangible assets	20,607	20,692
Property, plant and equipment	2,509	2,499
Right-of-use assets	393	382
Other financial assets	87	99
Other receivables	228	208
Deferred tax assets	258	238
Non-current assets	**24,082**	**24,118**
Inventories	4,513	4,427
Receivables	4,144	3,852
Cash and cash equivalents	5,113	5,010
Current assets	**13,770**	**13,289**
Assets	**37,852**	**37,407**
Equity and liabilities		
Share capital	996	996
Foreign currency translation reserve	1,314	1,109
Hedging reserve	(29)	63
Retained earnings	20,154	19,877
Equity	**22,435**	**22,045**
Retirement benefit obligations	221	216
Deferred tax liabilities	2,385	2,283
Provisions	413	388
Bank debt and bond debt	3,717	3,714
Lease liabilities	361	351
Other payables	451	420
Non-current liabilities	**7,548**	**7,372**
Retirement benefit obligations	1	1
Provisions	1,082	934
Trade payables	4,188	4,410
Lease liabilities	85	86
Income taxes payable	685	571
Other payables	1,828	1,988
Current liabilities	**7,869**	**7,990**
Liabilities	**15,417**	**15,362**
Equity and liabilities	**37,852**	**37,407**

STATEMENT OF CHANGES IN EQUITY

DKK million	Share capital	Foreign currency translation reserve	Hedging reserve	Retained earnings	Total equity
Equity at 1 January 2024	**996**	**1,109**	**63**	**19,877**	**22,045**
Profit for the period	-	-	-	1,006	1,006
Other comprehensive income	-	205	(92)	-	113
Comprehensive income	-	**205**	**(92)**	**1,006**	**1,119**
Distributed dividends, gross	-	-	-	(697)	(697)
Dividends received, treasury shares	-	-	-	3	3
Buyback of treasury shares	-	-	-	(43)	(43)
Incentive programs	-	-	-	7	7
Tax on other transactions in equity	-	-	-	1	1
Other transactions	-	-	**-**	**(729)**	**(729)**
Equity at 31 March 2024	**996**	**1,314**	**(29)**	**20,154**	**22,435**

DKK million	Share capital	Foreign currency translation reserve	Hedging reserve	Retained earnings	Total equity
Equity at 1 January 2023	**996**	**1,438**	**156**	**18,189**	**20,779**
Profit for the period	-	-	-	880	880
Other comprehensive income	-	(157)	89	-	(68)
Comprehensive income	-	**(157)**	**89**	**880**	**812**
Distribution of dividends, gross	-	-	-	(578)	(578)
Dividends received, treasury shares	-	-	-	2	2
Buyback of treasury shares	-	-	-	(43)	(43)
Incentive programs	-	-	-	8	8
Other transactions	-	-	**-**	**(611)**	**(611)**
Equity at 31 March 2023	**996**	**1,281**	**245**	**18,458**	**20,980**

CONDENSED STATEMENT OF CASH FLOWS

DKK million	Q1 2024	Q1 2023
Profit from operations (EBIT)	**1,278**	**1,233**
Adjustments for non-cash items	645	623
Change in working capital	(886)	(1,361)
Cash flows from operations before financial receipts and payments	**1,037**	**495**
Financial receipts and payments	32	(51)
Cash flows from ordinary activities	**1,069**	**444**
Income taxes paid	(108)	(66)
Cash flows from operating activities	**961**	**378**
Purchase and sale of intangible assets and property, plant and equipment	(94)	(77)
Cash flows from investing activities	**(94)**	**(77)**
Cash flows from operating and investing activities (free cash flow)	**867**	**301**
Repayment of bank loans and borrowings	-	(314)
Dividends paid in the financial year, net	(694)	(576)
Other financing activities	(66)	(65)
Cash flows from financing activities	**(760)**	**(955)**
Net cash flow for the period	**107**	**(654)**
Cash and cash equivalents at beginning of period	5,010	3,548
Unrealized exchange gains/losses on cash and cash equivalents	(4)	(12)
Net cash flow for the period	107	(654)
Cash and cash equivalent at end of period	**5,113**	**2,882**
Interest-bearing debt, cash, cash equivalents and securities, net, is composed as follows:		
Cash and cash equivalents	**5,113**	**2,882**
Interest-bearing debt	(4,314)	(5,373)
Net cash/(net debt)	**799**	**(2,491)**

STATEMENT OF PROFIT OR LOSS – ADJUSTED EBITDA RECONCILIATION (Q1)

	Q1 2024		Q1 2023	
DKK million	Reported	**Adjusted**	Reported	**Adjusted**
Revenue	**5,288**	**5,288**	**5,044**	**5,044**
Cost of sales	1,009	588	1,041	476
Gross profit	**4,279**	**4,700**	**4,003**	**4,568**
Sales and distribution costs	1,789	1,767	1,673	1,649
Administrative expenses	259	254	258	253
Research and development costs	953	933	839	821
Profit from operations (EBIT)	**1,278**	**-**	**1,233**	**-**
Depreciation/amortization	468	-	511	-
EBITDA	**1,746**	**1,746**	**1,744**	**1,845**
EBITDA margin	*33.0%*	*33.0%*	*34.6%*	*36.6%*
Adjustments to EBITDA				
Integration costs	-	-	-	-
Restructuring expenses	-	-	-	-
Gains/losses on divestment of businesses	-	-	-	-
Acquisition expenses	-	-	-	-
Other adjustments	-	-	101	-
Adjusted EBITDA	**1,746**	**1,746**	**1,845**	**1,845**
Adjusted EBITDA margin	*33.0%*	*33.0%*	*36.6%*	*36.6%*

4 NOTES

4.1 BASIS OF PREPARATION

The interim condensed consolidated financial statements for the three months ended 31 March 2024, have been prepared in accordance with IAS 34 Interim Financial Reporting as adopted by the EU and additional Danish disclosure requirements for interim financial reporting of listed companies. The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements and should be read in conjunction with the Group's annual consolidated financial statements at 31 December 2023, published 7 February 2024. The accounting policies, judgements and significant estimates are consistent with those applied in the Annual Report 2023.

Further IAS 34 disclosure requirements for interim financial reporting are included in section 2, *Business Performance*. For disclosures regarding revenue and segment information see section 2.1 *Revenue by product* and section 2.2 *Revenue by geographical area*, for disclosures regarding inventory obsolescence see section 2.4 *EBIT and adjusted EBITDA* and for disclosures regarding pending legal proceedings (contingent liabilities) see section 2.10 *General corporate matters*.

A number of new amendments came into effect from 1 January 2024. The Group did not have to change its accounting policies or make retrospective adjustments as a result of adopting these amended standards.

4.2 FAIR VALUE MEASUREMENT

Financial assets and financial liabilities measured or disclosed at fair value

DKK million 31 March 2024	Level 1	Level 2	Level 3
Financial assets			
Other financial assets[1]	32	-	28
Derivatives[1]	-	33	33
Total	**32**	**33**	**61**
Financial liabilities			
Contingent consideration[1]	-	-	355
Derivatives[1]	-	100	-
Bond debt[2]	3,371	-	-
Total	**3,371**	**100**	**355**

[1] Measured at fair value
[2] Disclosed at fair value

The fair value of listed securities is based on publicly quoted prices of the invested assets. The fair value of derivatives is calculated by applying recognized measurement techniques, whereby assumptions are based on the market conditions prevailing at the balance sheet date. The fair value of contingent consideration is calculated as the discounted cash outflows (DCF method) from future milestone payments, taking probability of success into consideration. The fair value of other financial assets is calculated through the financial performance of the market inputs (i.e. interest swap rates) and other market conditions prevailing at the balance sheet date.

4.3 ADJUSTED EBITDA

For the financial guidance 2024 and going forward, Lundbeck will focus on revenue and adjusted EBITDA at constant exchange rates (CER), instead of revenue and adjusted EBITDA at reported rates, to provide a more focused view of the underlying operational performance.

Adjusted EBITDA provides an improved and more consistent indicator, measuring the underlying operational profitability. Adjusted EBITDA enables a better understanding of the underlying operational performance, as the operating result is adjusted to exclude depreciation and amortization, impairment losses and reversals of impairment losses, as well as adjustments restricted to the following categories:

- Integration expenses,
- Restructuring expenses,
- Gains/losses on divestment of businesses,
- Acquisition expenses,
- Other adjustments.

Adjusted EBITDA, adjusted gross profit and adjusted EPS are non-IFRS performance measures.

FINANCIAL CALENDAR 2024

21 August 2024:	Financial statements for the first six months of 2024
13 November 2024:	Financial statements for the first nine months of 2024
5 February 2025:	Corporate release for the full year 2024
5 February 2025:	Annual Report 2024

Lundbeck contacts

Investors:

Palle Holm Olesen
Vice President, Investor Relations
PALO@lundbeck.com
+45 30 83 24 26

Media:

Thomas Mikkel Mortensen
Media Relations Lead
THMR@lundbeck.com
+45 30 83 30 24

About Lundbeck

Lundbeck is a biopharmaceutical company focused exclusively on neuroscience, with more than 70 years of experience in improving the lives of people with neurological and psychiatric diseases.

As a focused innovator, we strive for our research and development programs to tackle some of the most complex challenges. We develop transformative medicines targeting people for whom there are few, if any, treatment options. Our goal is to create long term value and make a positive contribution to people and societies, everywhere we operate. We are committed to fighting stigma and discrimination, and we act to improve health equity for the people we serve and the communities we are part of.

Too many people worldwide live with brain diseases – complex conditions often invisible to others that nonetheless take a tremendous toll on individuals, families and societies. We are committed to fighting stigma and discrimination against people living with brain diseases and advocating for broader social acceptance of people with brain health conditions. Every day, we strive for improved treatment and a better life for people living with brain disease.

We have approximately 5,700 employees, and our products are available in more than 100 countries. Our research programs tackle some of the most complex challenges in neuroscience, and our pipeline is focused on bringing forward transformative treatments for brain diseases for which there are few, if any therapeutic options. We have research facilities in Denmark and the United States, and our production facilities are located in Denmark, France, and Italy.

For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Instagram (h_lundbeck) and via LinkedIn.